Changes in Intraocular Pressure After Intravitreal Injection

Monitoring Changes in Intraocular Pressure After Intravitreal Injection

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07826286

Enrollment

Registered

2026-09-17

Start date

2026-10-01

Completion date

2027-11-01

Last updated

2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration, Ocular Hypertension, Retinal Vein Occlusion

Keywords

Intraocular Pressure, Intravitreal Injections, Anti-VEGF, Icare Tonometry, Rebound Tonometry, Bevacizumab, Ranibizumab

Brief summary

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections introduce additional fluid volume into the eye, which can cause an acute, transient elevation in intraocular pressure (IOP). The purpose of this prospective observational study is to evaluate the immediate and early changes in intraocular pressure following intravitreal anti-VEGF injections and to determine how rapidly pressure recovers toward baseline levels. Adult participants scheduled to receive routine intravitreal anti-VEGF therapy for established clinical indications, such as diabetic macular edema, neovascular age-related macular degeneration, or retinal vein occlusion, will be enrolled. Intraocular pressure will be measured using an Icare rebound tonometer with single-use disposable probes before injection (baseline) and at 1 minute, 5 minutes, and 20 minutes post-injection. The study will also analyze whether factors such as refractive error, the number of prior injections, or the type of anti-VEGF drug administered affect the severity of post-injection pressure spikes and subsequent recovery.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Age 18 years or older. * Scheduled to receive an intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for an established clinical indication (e.g., diabetic macular edema, neovascular age-related macular degeneration, or retinal vein occlusion). * Provision of written informed consent prior to enrollment.

Exclusion criteria

* Known history of glaucoma or ocular hypertension. * History of previous glaucoma surgery. * Corneal diseases or ocular conditions that significantly interfere with accurate intraocular pressure measurement. * Inability to cooperate adequately during intraocular pressure measurement. * Refusal to participate or failure to provide informed consent. * Development of marked intraocular pressure elevation immediately after injection (IOP ≥ 40 mmHg) requiring anterior chamber paracentesis.

Design outcomes

Primary

Measure	Time frame	Description
Change from Baseline in Intraocular Pressure at 1 Minute	Baseline and 1 minute post-injection	Intraocular pressure will be measured in mmHg using an Icare rebound tonometer with a single-use disposable probe to assess the acute post-injection pressure spike compared to baseline.
Change from Baseline in Intraocular Pressure at 5 Minutes	Baseline and 5 minutes post-injection	Intraocular pressure will be measured in mmHg using an Icare rebound tonometer with a single-use disposable probe to evaluate early post-injection pressure trends.
Change from Baseline in Intraocular Pressure at 20 Minutes	Baseline and 20 minutes post-injection	Intraocular pressure will be measured in mmHg using an Icare rebound tonometer to assess the rate and extent of pressure recovery toward pre-injection baseline levels.

Outcome results